Gene expression profiling (GEP) is currently the best approach for defining risk in multiple myeloma (MM). Mutation detection may be used for improving risk stratification and providing additional… read more.
Specialists in the MM field are in the enviable position of having lots of different treatment options available – the challenge is how to integrate these into the… read more.
Multiple myeloma is unique amongst cancers in that the diagnosis is made by the clinician, not the pathologist. The pathologist merely states that the patient has a clonal… read more.
IMW President, Professor Antonio Palumbo (Torino, Italy) gives his highlights, along with Dr Noopar Raje (Boston, USA) , Professor Faith Davies, (Little Rock, USA) and Professor Paul Richardson (Boston, USA).
by Bruce Sylvester: Researchers report that a genetically engineered vaccine, VGX-3100/ Inovio Pharmaceuticals, appears to eradicate high-grade precancerous cervical lesions in some women. The findings from a phase 2b… read more.
by Bruce Sylvester: Men who have had a heart attack and then receive androgen deprivation therapy (ADT) for prostate cancer are at an increased risk of subsequent fatal… read more.
by Gary Finnegan: Netherlands: Women with breast cancer who follow a physical exercise programme during their chemotherapy treatment experience fewer side effects, according a study by the Netherlands… read more.
Men with asthma are less likely to have aggressive prostate cancer or to die from the disease, according to a large, prospective cohort study published in the International… read more.
Firmagon (Degarelix) is a competitive, reversible GnRH receptor blocker, for patients with advanced hormone-dependent prostate cancer. Where Injection technique is critical; Nora Sullivan, a specialist nurse at Hibernian… read more.
by Bruce Sylvester: Among patients with metastatic hormone-sensitive prostate cancer, chemotherapy with docetaxel at the start of androgen deprivation therapy (ADT) has resulted in an increased survival of… read more.
by Bruce Sylvester: Treatment of diabetes with pioglitazone does not appear to be related to an increased risk of bladder cancer, researchers from an analysis including nearly 200,000… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
